IN Brief:
- Scotland’s planned Monklands replacement hospital has been sent back for redesign.
- Ministers refused to approve the £2.1bn business case on affordability grounds.
- Revised plans are expected to return for ministerial consideration in 2027.
Laing O’Rourke faces renewed uncertainty on the planned Monklands Replacement Project after Scottish ministers refused to approve the £2.1bn business case and ordered the scheme to be redesigned.
The project had been intended to deliver a new acute hospital at Wester Moffat, near Airdrie, replacing the existing University Hospital Monklands. Laing O’Rourke was appointed as construction partner in 2023 and had already been carrying out enabling and preparatory earthworks at the site.
Scottish Health Secretary Angela Constance said the current full business case could not be approved within the government’s financial position, while confirming that the need to replace the existing hospital remains accepted. A comprehensive redesign is now due to begin between the Scottish Government, NHS Lanarkshire, and partners across the west of Scotland.
Refreshed plans are expected to return to ministers for a decision in 2027. While the redesign progresses, targeted investment will be made in the existing Monklands Hospital to address immediate infrastructure pressures, and the government has said core services, including A&E, will be retained in the future acute hospital.
Sending the scheme back into design creates a difficult pause for one of Scotland’s most significant NHS capital projects. Previous plans had promoted a digitally enabled and low-carbon hospital, with ambitions around net zero performance and modern clinical delivery. Those aims now have to be tested against a more constrained capital envelope.
Healthcare construction gives clients little room for easy savings. Acute hospitals carry heavy MEP content, specialist ventilation, medical gases, infection control systems, clinical adjacencies, resilience requirements, and complex commissioning processes. Once those requirements are embedded, reducing scope without weakening the operational brief becomes a difficult exercise.
Large public building programmes are also being exposed to the long lag between early business cases and final approval. Construction inflation, labour availability, building safety requirements, energy performance standards, and public borrowing pressure can all change materially before a project reaches the point of commitment. Monklands now joins a growing group of public-sector schemes being asked to reconcile modern performance expectations with budgets shaped by a harsher funding environment.
The supply chain impact begins before a main contract is fully released. Enabling works, design development, consultant appointments, early subcontractor engagement, and local employment expectations all create momentum. A redesign can protect affordability, but it can also push cost into remobilisation, redesign fees, programme delay, and the continued maintenance of an ageing estate.
Ministers have framed the move as a reset rather than a cancellation, and NHS Lanarkshire has said it will work with government to progress a deliverable replacement. The construction question is how much of the current design, procurement structure, and early works activity can survive the affordability review. If the redesign is too radical, previous development work may lose value; if it is too cautious, the revised scheme may remain exposed to the same cost pressures.
Across healthcare construction, clients are under growing pressure to use standardisation, repeatable design components, and clearer phasing strategies to control cost. The difficulty is that hospitals are shaped by local clinical models, estate constraints, workforce needs, and service continuity. Platform approaches can help, but they rarely remove the need for tailored design in complex acute settings.
Monklands will now be watched as a test of whether a major hospital scheme can be made more affordable without losing the clinical and technical improvements that justified replacement. Until the revised plans return in 2027, the project remains publicly committed, clinically needed, and technically advanced, but no longer approved in its existing form. That is an awkward position for any delivery team, particularly one already engaged on the ground.
